search
Back to results

Temporary Epicardial Pace Wire With Integrated Sensor for Continuous Postoperative Monitoring of Myocardial Function

Primary Purpose

Cardiac Disease, Myocardial Dysfunction

Status
Enrolling by invitation
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
CS1 System
Sponsored by
Cardiaccs AS
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Cardiac Disease

Eligibility Criteria

19 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients with heart disease requiring surgery
  2. Above 18 years
  3. Patients suitable for study participation without safety concerns based on the Investigator's evaluation of medical history and physical examination.
  4. The patient must be able to understand the aims and objectives of the trial, willing and able to comply with all study related procedures
  5. The patient must be willing and able to provide written informed consent prior to participation in the clinical investigation
  6. The patient agrees to abstain from enrollment in any other clinical investigation for the duration of the study

Exclusion Criteria:

  1. Esophageal disease
  2. Atrial fibrillation
  3. Pregnancy

Sites / Locations

  • Oslo University Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Safety and clinical performance of the CS1 system

Arm Description

Placement of the CS1 device on the left ventricle and externalization of the associated leads through the chest wall during open-heart surgery.

Outcomes

Primary Outcome Measures

Change from Baseline Peak Systolic Velocity (PSV) after increasing heart rate by 25 percent
Correlation between relative changes in PSVs measured by CS1 and echocardiography
Change from Baseline PSV after increasing heart rate by 25 percent
Correlation between relative changes in PSVs measured by CS1 and echocardiography

Secondary Outcome Measures

Adverse Events
Incidence of non-serious and serious adverse events rated for causality
Adverse Device Effects
Incidence of non-serious and serious adverse device-related effects
Device Deficiencies
Incidence of device deficiencies

Full Information

First Posted
May 3, 2021
Last Updated
January 11, 2023
Sponsor
Cardiaccs AS
Collaborators
European Commission
search

1. Study Identification

Unique Protocol Identification Number
NCT04886934
Brief Title
Temporary Epicardial Pace Wire With Integrated Sensor for Continuous Postoperative Monitoring of Myocardial Function
Official Title
Open Clinical Investigation to Assess Performance of a Temporary Epicardial Pace Wire With Integrated Sensor for Continuous Postoperative Monitoring of Myocardial Function After Heart Surgery Compared to Ultrasound
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
October 25, 2021 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
August 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cardiaccs AS
Collaborators
European Commission

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Transesophageal echocardiography is used to monitor cardiac wall motion at various time points during open-heart surgery. After surgery, the measurements are made at various time points by transthoracic echocardiography. The CS1 system enables continuous, direct measurement of cardiac wall motion. This is achieved through use of temporary pacemaker wires incorporating a motion detector called an accelerometer. Use of TMEs during and after open-heart surgery is part of the normal clinical routine. Continuous monitoring of cardiac wall motion during and after surgery can quickly highlight the need for medical intervention with cardiac drugs and allow very early detection of potentially serious complications leading to abnormal cardiac wall motion. Cardiac wall motion activity registered by the CS1 system and echocardiography at specific time points during and after surgery will be analyzed to see how well they compare.
Detailed Description
Echocardiography is currently the most important and most widely used tool in cardiology besides electrocardiography (ECG). It is reliable for assessing all stages of cardiovascular disease, and it is commonly used to detect heart (cardiac) wall motion dysfunction during and after open-heart surgery. During open-heart surgery, transesophageal echocardiography (when the echocardiography sensor is introduced into the esophagus) is used to monitor cardiac wall motion at various time points during surgery. After surgery, the measurements are made at various time points by transthoracic echocardiography (when the echocardiography sensor is placed on the chest wall). Use of the CS1 system enables continuous, direct measurements of cardiac wall motion. This is achieved through use of temporary pacemaker wires (also called temporary myocardial electrodes or TMEs) incorporating a motion detector called an accelerometer. Use of TMEs during and after open-heart surgery is part of the normal clinical routine. Continuous monitoring of cardiac wall motion during the surgery and the post-surgical recovery period can, for example, quickly highlight the need for medical intervention with cardiac drugs and allow very early detection of potentially serious complications such as ischemia (heart muscle is not receiving enough oxygen) and myocardial dysfunction (cardiac wall motion appears abnormal). The key feature of the CS1 system is that the cardiac wall motion activity registered by the novel TMEs incorporating the accelerometer are displayed visually on a standard medical monitor and synchronized with the patient's ECG data. These data can easily be viewed by medical staff to check if the patient's condition is satisfactory or whether medical intervention is needed. In the study, the CS1 system will be used in addition to the standard monitoring procedures that include ECG, blood pressures and intermittent echocardiography. Cardiac wall motion activity registered by the CS1 system and echocardiography at specific time points during and after surgery will be analyzed to see how well they compare.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiac Disease, Myocardial Dysfunction

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
38 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Safety and clinical performance of the CS1 system
Arm Type
Experimental
Arm Description
Placement of the CS1 device on the left ventricle and externalization of the associated leads through the chest wall during open-heart surgery.
Intervention Type
Device
Intervention Name(s)
CS1 System
Intervention Description
Placement of CS1, a temporary bipolar myocardial electrode (TME) with an integrated motion sensor (accelerometer), on the left ventricle and externalization of the associated leads through the chest wall during open-heart surgery. CS1 will remain in place for up to 7 days after surgery and closure of the chest wall.
Primary Outcome Measure Information:
Title
Change from Baseline Peak Systolic Velocity (PSV) after increasing heart rate by 25 percent
Description
Correlation between relative changes in PSVs measured by CS1 and echocardiography
Time Frame
After surgery: before extubation, while patient is in the intensive care unit (ICU)
Title
Change from Baseline PSV after increasing heart rate by 25 percent
Description
Correlation between relative changes in PSVs measured by CS1 and echocardiography
Time Frame
After surgery: after extubation and removal of drains, before patient is transferred from ICU to general ward
Secondary Outcome Measure Information:
Title
Adverse Events
Description
Incidence of non-serious and serious adverse events rated for causality
Time Frame
Up to 30 days after surgery
Title
Adverse Device Effects
Description
Incidence of non-serious and serious adverse device-related effects
Time Frame
Up to removal of device at a maximum of 7 days after surgery
Title
Device Deficiencies
Description
Incidence of device deficiencies
Time Frame
Up to removal of device at a maximum of 7 days after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with heart disease requiring surgery Above 18 years Patients suitable for study participation without safety concerns based on the Investigator's evaluation of medical history and physical examination. The patient must be able to understand the aims and objectives of the trial, willing and able to comply with all study related procedures The patient must be willing and able to provide written informed consent prior to participation in the clinical investigation The patient agrees to abstain from enrollment in any other clinical investigation for the duration of the study Exclusion Criteria: Esophageal disease Atrial fibrillation Pregnancy
Facility Information:
Facility Name
Oslo University Hospital
City
Oslo
ZIP/Postal Code
4950
Country
Norway

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Temporary Epicardial Pace Wire With Integrated Sensor for Continuous Postoperative Monitoring of Myocardial Function

We'll reach out to this number within 24 hrs